Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Ovarian Research

Fig. 1

From: Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer

Fig. 1

p53 at the Mitochondria. p53 activates pro-apoptotic factors Bak and Bax, which homo-oligomerize and recruit factors to form mitochondrial pores, leading to the release of cytochrome C, activation of the apoptosome, the caspase cascade, and apoptosis [10]. p53 also inactivates anti-apoptotic factors Bcl-W, Mcl-1, Bcl-2, and Bcl-xL, which function by binding Bak and Bax, thus preventing their homo-oligomerization and, therefore, apoptosis [38]

Back to article page